Xvivo Perfusion Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 5/6

Xvivo Perfusion verzeichnete einen durchschnittlichen jährlichen Gewinnzuwachs von 51.1%, während die Gewinne der Branche Medical Equipment jährlich um gewachsen und zwar um 17%. Die Umsätze verzeichneten einen durchschnittlichen jährlichen Gewinnzuwachs von gewachsen von 27.6%. Die Eigenkapitalrendite von Xvivo Perfusion beträgt 5% und die Nettomargen betragen 15.6%.

Wichtige Informationen

51.1%

Wachstumsrate der Gewinne

49.0%

EPS-Wachstumsrate

Medical Equipment Wachstum der Industrie	6.2%
Wachstumsrate der Einnahmen	27.6%
Eigenkapitalrendite	5.0%
Netto-Marge	15.6%
Nächste Ertragsaktualisierung	12 Jul 2024

Jüngste Aktualisierungen vergangener Leistungen

We Think That There Are Issues Underlying Xvivo Perfusion's (STO:XVIVO) Earnings

Feb 01

Recent updates

Xvivo Perfusion AB (publ) (STO:XVIVO) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected

Apr 25

There Are Reasons To Feel Uneasy About Xvivo Perfusion's (STO:XVIVO) Returns On Capital

Apr 11

Need To Know: Analysts Just Made A Substantial Cut To Their Xvivo Perfusion AB (publ) (STO:XVIVO) Estimates

Feb 05

We Think That There Are Issues Underlying Xvivo Perfusion's (STO:XVIVO) Earnings

Feb 01

Earnings Beat: Xvivo Perfusion AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jan 28

Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 35% Undervaluation?

Nov 17

Xvivo Perfusion (STO:XVIVO) Might Be Having Difficulty Using Its Capital Effectively

Aug 20

Statutory Profit Doesn't Reflect How Good Xvivo Perfusion's (STO:XVIVO) Earnings Are

Jul 21

Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital

Mar 30

At kr258, Is Xvivo Perfusion AB (publ) (STO:XVIVO) Worth Looking At Closely?

Feb 18

A Look At The Fair Value Of Xvivo Perfusion AB (publ) (STO:XVIVO)

Jan 30

Calculating The Intrinsic Value Of Xvivo Perfusion AB (publ) (STO:XVIVO)

Apr 09

Should You Think About Buying Xvivo Perfusion AB (publ) (STO:XVIVO) Now?

Mar 19

What Type Of Shareholders Own The Most Number of Xvivo Perfusion AB (publ) (STO:XVIVO) Shares?

Feb 26

Have Insiders Been Buying Xvivo Perfusion AB (publ) (STO:XVIVO) Shares?

Feb 05

Aufschlüsselung der Einnahmen und Ausgaben

Wie Xvivo Perfusion Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

OM:XVIVO Einnahmen, Ausgaben und Erträge (SEK Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten	F&E-Ausgaben
31 Mar 24	643	100	328	140
31 Dec 23	598	92	309	136
30 Sep 23	573	24	287	109
30 Jun 23	524	27	253	98
31 Mar 23	463	28	247	79
31 Dec 22	415	18	223	69
30 Sep 22	370	30	211	61
30 Jun 22	328	23	186	55
31 Mar 22	293	7	171	58
31 Dec 21	258	8	153	54
30 Sep 21	233	-24	135	65
30 Jun 21	221	-37	137	66
31 Mar 21	192	-44	116	63
31 Dec 20	180	-44	108	67
30 Sep 20	182	-26	95	58
30 Jun 20	194	-6	79	64
31 Mar 20	220	12	87	65
31 Dec 19	221	5	93	63
30 Sep 19	217	12	86	57
30 Jun 19	203	7	86	52
31 Mar 19	193	9	79	51
31 Dec 18	188	13	70	48
30 Sep 18	171	13	68	45
30 Jun 18	162	13	67	43
31 Mar 18	153	10	62	41
31 Dec 17	148	6	64	39
30 Sep 17	145	0	60	40
30 Jun 17	145	0	63	41
31 Mar 17	142	0	61	39
31 Dec 16	138	2	56	37
30 Sep 16	132	5	56	34
30 Jun 16	127	7	46	32
31 Mar 16	122	6	46	32
31 Dec 15	120	5	45	31
30 Sep 15	113	4	42	33
30 Jun 15	109	4	40	31
31 Mar 15	98	3	37	26
31 Dec 14	85	5	34	23
30 Sep 14	79	6	33	18
30 Jun 14	74	7	32	17
31 Mar 14	71	7	30	16
31 Dec 13	69	8	29	15
30 Sep 13	64	5	30	13
30 Jun 13	62	2	30	10

Qualität der Erträge: XVIVO hat hohe Qualitätseinkünfte.

Wachsende Gewinnspanne: XVIVODie aktuellen Gewinnspannen (15.6%) sind höher als im letzten Jahr (6%).

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: XVIVOIn den letzten 5 Jahren sind die Einnahmen von 51.1% pro Jahr erheblich gestiegen.

Beschleunigtes Wachstum: XVIVODas Gewinnwachstum des Unternehmens im letzten Jahr (260.8%) übertrifft seinen 5-Jahres-Durchschnitt (51.1% pro Jahr).

Erträge im Vergleich zur Industrie: XVIVO Das Gewinnwachstum im vergangenen Jahr (260.8%) übertraf das der Branche Medical Equipment 41.1% .

Eigenkapitalrendite

Hohe Eigenkapitalrendite: XVIVODie Eigenkapitalrendite des Unternehmens (5%) wird als niedrig angesehen.

Xvivo Perfusion Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

We Think That There Are Issues Underlying Xvivo Perfusion's (STO:XVIVO) Earnings

Third quarter 2023 earnings released: EPS: kr0.076 (vs kr0.18 in 3Q 2022)

Xvivo Perfusion AB (publ) to Report First Half, 2024 Results on Jul 12, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Recent updates

Independent Director recently bought kr222k worth of stock

Consensus EPS estimates increase by 27%

Xvivo Perfusion AB (publ) (STO:XVIVO) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Xvivo Perfusion AB (publ) Announces Results from Clinical Trial NIHP2019 for Heart Preservation Presented at ISHLT in Prague

Consensus EPS estimates increase by 16%

There Are Reasons To Feel Uneasy About Xvivo Perfusion's (STO:XVIVO) Returns On Capital

Consensus EPS estimates increase by 17%, revenue downgraded

Need To Know: Analysts Just Made A Substantial Cut To Their Xvivo Perfusion AB (publ) (STO:XVIVO) Estimates

We Think That There Are Issues Underlying Xvivo Perfusion's (STO:XVIVO) Earnings

Chairman of the Board recently bought kr281k worth of stock

Earnings Beat: Xvivo Perfusion AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Third quarter 2023 earnings released: EPS: kr0.076 (vs kr0.18 in 3Q 2022)

Xvivo Perfusion AB (publ) to Report First Half, 2024 Results on Jul 12, 2024

Price target increased by 7.9% to kr407

Consensus EPS estimates fall by 13%

Price target increased by 8.0% to kr407

Chairman of the Board recently bought kr125k worth of stock

Xvivo Perfusion AB (publ) Announces Results from A Australian/New Zealand Study Using Xvivo's Heart Technology Published

Consensus EPS estimates fall by 24%

Xvivo Perfusion AB (publ) Announces Leading Acacemic Medical Center Performs First Heart Transplant in the U.S. Utilizing NIHP Technology as Part of Xvivo's Preserve Clinical Trial

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Xvivo Perfusion AB (publ), Annual General Meeting, Apr 25, 2024

Now 24% undervalued

New minor risk - Shareholder dilution

Returns On Capital At Xvivo Perfusion (STO:XVIVO) Have Stalled

Consensus EPS estimates increase by 42%

US Food & Drug Administration Grants Xvivo Perfusion AB (publ) Approval to Include DCD Heartarts in IDE Clinical Trial

Consensus EPS estimates fall by 33%

Why Xvivo Perfusion AB (publ) (STO:XVIVO) Could Be Worth Watching

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Xvivo Perfusion AB (publ) Announces Its Decision to Close the PrimECC(R) Study for Further Patient Inclusions - Strategic Opportunities Will Be Evaluated

Consensus EPS estimates fall by 12%

Do Xvivo Perfusion's (STO:XVIVO) Earnings Warrant Your Attention?

Xvivo Announces Patient Inclusion Completed in European Clinical Trial with Heart Preservation Technology

Consensus revenue estimates increase by 10%

Independent Director recently bought kr107k worth of stock

Consensus EPS estimates fall by 30%

Xvivo Perfusion (STO:XVIVO) May Have Issues Allocating Its Capital

Now 22% undervalued

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 22% undervalued

Are Investors Undervaluing Xvivo Perfusion AB (publ) (STO:XVIVO) By 21%?

With EPS Growth And More, Xvivo Perfusion (STO:XVIVO) Makes An Interesting Case

When Should You Buy Xvivo Perfusion AB (publ) (STO:XVIVO)?

Now 21% undervalued

Full year 2022 earnings released: EPS: kr0.62 (vs kr0.28 in FY 2021)

Xvivo Perfusion AB (publ), Annual General Meeting, Apr 25, 2023

Consensus EPS estimates fall by 12%

Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital

XVIVO Perfusion AB (Publ) Appoints Christoffer Rosenblad as CEO

XXvivo Perfusion AB (publ) Appoints Lena Hagman to Chief Operating Officer, COO

Consensus EPS estimates increase by 14%

Xvivo Perfusion AB (Publ) Presents Positive Results from the Australian & New Zealand Heart Preservation Study

Consensus EPS estimates increase by 14%

Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 35% Undervaluation?

Chairman of the Board recently bought kr201k worth of stock

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Xvivo Perfusion AB (publ) Announces CEO Changes

XVIVO Perfusion AB Receives Breakthrough Device Designation Grant from the FDA for the Liver Assist Device

Xvivo Perfusion (STO:XVIVO) Might Be Having Difficulty Using Its Capital Effectively

Xvivo Perfusion AB (publ) (OM:XVIVO) signed an agreement to acquire Machine and perfusion business from Avionord Srl for €12 million.

Statutory Profit Doesn't Reflect How Good Xvivo Perfusion's (STO:XVIVO) Earnings Are

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

President & CEO exercised options to buy kr1.3m worth of stock.

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Full year 2021 earnings: EPS and revenues miss analyst expectations